Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $34 | $0 |
| % Growth | 48.4% | -99.8% | 105,767.6% | – |
| Cost of Goods Sold | $0 | $0 | $18 | $0 |
| Gross Profit | $0 | $0 | $17 | $0 |
| % Margin | 47.7% | 46.5% | 48.6% | 45.9% |
| R&D Expenses | $0 | $0 | $6 | $0 |
| G&A Expenses | $0 | $0 | $5 | $0 |
| SG&A Expenses | $0 | $0 | $5 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2 | $0 |
| Operating Expenses | $0 | $0 | $13 | $0 |
| Operating Income | $0 | $0 | $2 | $0 |
| % Margin | 23.3% | 19.1% | 5.9% | 15.7% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | $4 | $0 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | $0 | $4 | $0 |
| % Margin | -5.1% | 35.5% | 12.9% | 27.6% |
| EPS | -0.004 | 0.02 | 4.35 | 0.009 |
| % Growth | -120.2% | -99.5% | 49,331.8% | – |
| EPS Diluted | -0.004 | 0.02 | 4.35 | 0.007 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 3.4% | 4.5% | 0% | 20.1% |